Detailed Product Description

Valnemulin, a member of the pleuromutilin group which also includes tiamulin, is new drug intended exclusively for veterinary use. This drug is the effective substitute for tiamulin. Valnemulin was approved originally in 1999 by the European Union (EU) for the prevention and treatment of swine dysentery caused by Brachyspira hyodysenteriae and enzootic pneumonia caused by Mycoplasma hyopneumoniae. Valnemulin was approved in 2004 by the European Union (EU) for treatment of clinical signs of porcine proliferative enteropathy(ileitis) and the prevention of clinical signs of porcine colonic spirochaetosis(colitis) .Recent work has showed that valnemulin is also highly active against B. pilosicoli, a spirochaete highly similar to B. hyodysenteriae, which causes porcine spirochaetal diarrhoea or colitis, a milder form of diarrhoea in grower pigs. It has also been shown to have a high level of intracellular activity against Lawsonia intracellularis, the cause of porcine proliferative enteropathy or ileitis. The paper reviews the clinical trial work, both artificial challenge models and field studies, that enabled valnemulin to be recently approved for the prevention of colitis and treatment of ileitis in the EU.

To some extent, the efficacy of Valnemulin is about 100 times larger than Tiamulin, about 200 times larger than Enrofloxin and Tolysin.

This drug has the following merits:

1. Low dosage

2. Low toxicity

3. Low residua

4. High efficacy.